Transplatin

Summary

Transplatin (CHEMBL1386) is a phase-3 clinical-stage small molecule; indicated across 7 conditions including diffuse large b-cell lymphoma and plasma cell myeloma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 7 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1386
Name	Transplatin
Type	Small molecule
Max phase	3

Also known as: NSC-131558, Trans-ddp, Trans-diaminedichloroplatinum, Trans-diamminedichloroplatinum, Transplatin, Trans-[PtCl2(NH3)2] complex, transplatin, trans-ptcl2(NH3)2, SID26748616, SID124891673, Trans-Platinum (II)Diammine Dichloride, TRANS-PLATINUM(II)DIAMMINE DICHLORIDE

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Tyrosine-protein kinase Fyn, Epidermal growth factor receptor, Muscarinic acetylcholine receptor M5, D(3) dopamine receptor, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ALOX15	6.5	Potency	316.2	nM	CHEMBL_ACT_4466743
ADORA3	6.25	Ki	559	nM	CHEMBL_ACT_7788683
FYN	6.25	IC50	564.5	nM	CHEMBL_ACT_7790479
TDP1	6	Potency	1000	nM	CHEMBL_ACT_3931666
ADORA3	6	IC50	989.1	nM	CHEMBL_ACT_7788682
EGFR	5.97	IC50	1063	nM	CHEMBL_ACT_7790477
DRD3	5.95	Ki	1129	nM	CHEMBL_ACT_7789564
MAPT	5.65	Potency	2239	nM	CHEMBL_ACT_4529381
MAPT	5.6	Potency	2512	nM	CHEMBL_ACT_4061338
LCK	5.57	IC50	2721	nM	CHEMBL_ACT_7790483
DRD3	5.48	IC50	3324	nM	CHEMBL_ACT_7789563
CHRM5	5.37	Ki	4257	nM	CHEMBL_ACT_7789630
KDM4E	5.3	Potency	5012	nM	CHEMBL_ACT_3745246
CHRM5	5.23	IC50	5925	nM	CHEMBL_ACT_7789629
ALDH1A1	5	Potency	10000	nM	CHEMBL_ACT_4171425

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
ependymoma	2	MONDO:0016698	MONDO:0003478
oropharynx cancer	2	MONDO:0004608	MONDO:0021364
malignant pleural mesothelioma	1	MONDO:0005112	EFO:0000770

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).